Friday, July 10, 2026

pharma · Invasive Extraintestinal Pathogenic Escherichia coli Disease · HIV-1 Infection

Zhejiang Xianju Pharmaceutical

Zhejiang Xianju Pharmaceutical clinical programs — 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

西安, CN HQ
146 Employees
NMPA registrant Type
Company details
Status
Public
HQ
西安, CN
Employees
146
Programs
2
Drugs
5
Patents
0
Intelligence · Clinical Programs

Zhejiang Xianju Pharmaceutical projects

1 ClinicalTrials.gov programs sponsored by Zhejiang Xianju Pharmaceutical.

Zhejiang Xianju Pharmaceutical has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. RILPIVIRINE , JNJ-16150108

    Xian-Janssen Pharmaceutical

    HIV-1 Infection

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Zhejiang Xianju Pharmaceutical have?

1 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.